Ascenta Capital
Ascenta Capital is a biotechnology-focused venture capital firm that invests in early-stage biotech companies developing multiple therapeutic medicines from a common platform. Based in New York and founded in 2023, the firm supports portfolio companies through clinical, regulatory, manufacturing, and capital strategy needs, working closely with management to advance programs through Phase 1 and Phase 2 trials. Its portfolio approach balances risk by backing multi-asset platforms rather than single-asset programs.
Top Sectors
Top Regions
Top Stages
2 past transactions
OrsoBio
Series B in 2024
OrsoBio is a clinical-stage biopharmaceutical company focused on developing therapies for severe metabolic disorders such as diabetes, dyslipidemia, and lipodystrophies. It aims to restore energy homeostasis by targeting pathways relevant to maintaining energy balance.
ADARx Pharmaceuticals
Series B in 2023
ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.